Cartesian Therapeutics Bolsa (NASDAQ: RNAC)

Últimas noticias sobre Cartesian Therapeutics (NASDAQ:RNAC) Bolsa

CARTESIAN THERAPEUTICS INC

Cartesian Therapeutics

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.

Movimiento de acciones

AEHL

AMBC

BTOG

CCCS

DGICA

EHAB

FFIC

FMTO

IXHL

RNAC

SDHC

SVRE

TNMG

VERO

VINC

VNOM

WORX

Acciones en alza y en caída antes del mercado: descubre qué impulsó los mayores movimientos bursátiles del día.

Acciones de Venus Concept (VERO) se disparan un 200%; aquí están 20 acciones que se mueven en premercado

Movers_Stocks

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADPT

CXAI

ENTO

HRTG

IIIN

LION

LSAK

MLNK

MULN

OLMA

SGMO

SHCO

SLSR

Sangamo Therapeutics se dispara tras anunciar un acuerdo exclusivo con Eli Lilly sobre tecnología genética patentada. ¿Qué implica esto?

Acciones de Sangamo Therapeutics (SGMO) se disparan un 40%; Aquí están 20 acciones que se mueven en premercado

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics Inc

Across the recent three months, 9 analysts have shared their insights on Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $45.56, with a high estimate of $52.00 and a low estimate of $39.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 3.31%. 
<img src="https://www.benzinga.com/files/images/story/2025/1750078837_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Freeport-McMoRan among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orest Wowkodaw</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$48.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Orest Wowkodaw</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$43.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Chris LaFemina</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Timna Tanners</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$39.00</td>
<td>-</td>
</tr>
<tr>
<td>Daniel Major</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Bill Peterson</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Orest Wowkodaw</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$40.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Brian MacArthur</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$51.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Bill Peterson</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$52.00</td>
<td>$48.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Freeport-McMoRan. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Freeport-McMoRan compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Freeport-McMoRan's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Freeport-McMoRan's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FCX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Freeport-McMoRan analyst ratings.</a>
<h2>About Freeport-McMoRan</h2>
Freeport-McMoRan owns stakes in 10 copper mines, led by its 49% ownership of the Grasberg copper and gold operations in Indonesia, 55% of the Cerro Verde mine in Peru, and 72% of Morenci in Arizona. It sold around 1.2 million metric tons of copper (its share) in 2024, making it the one of the world's largest copper miners by volume. It also sold about 900,000 ounces of gold, mostly from Grasberg, and 70 million pounds of molybdenum. It had about 25 years of copper reserves at the end of December 2024. We expect it to sell similar amounts of copper midcycle in 2029, though we expect gold volumes to decline to about 700,000 ounces then due to falling production at Grasberg.
<h3>Key Indicators: Freeport-McMoRan's Financial Health</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Challenges: Freeport-McMoRan's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -9.38%. This indicates a decrease in top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Freeport-McMoRan's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 6.15%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Freeport-McMoRan's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.0%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Freeport-McMoRan's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.64%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Freeport-McMoRan's debt-to-equity ratio stands notably higher than the industry average, reaching 0.53. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Breaking Down Freeport-McMoRan: 9 Analysts Share Their Views

Target's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) short percent of float has fallen 18.91% since its last report. The company recently reported that it has 16.15 million shares sold short, which is 3.56% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.67 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Target Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750078832_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Target has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Target's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Target's peer group average for short interest as a percentage of float is 4.53%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Target's Recent Short Interest

Kimco Realty's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIM#NYSE">KIM</a>) short percent of float has fallen 12.77% since its last report. The company recently reported that it has 17.95 million shares sold short, which is 3.62% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.53 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Kimco Realty Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750078827_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Kimco Realty has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Kimco Realty's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Kimco Realty's peer group average for short interest as a percentage of float is 5.89%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

What's Driving the Market Sentiment Around Kimco Realty?

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Martin Marietta Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Martin Marietta Materials, revealing an average target of $574.62, a high estimate of $634.00, and a low estimate of $491.00. A decline of 2.96% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1750078825_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Martin Marietta Materials. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Codling</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$515.00</td>
<td>-</td>
</tr>
<tr>
<td>Steven Fisher</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$634.00</td>
<td>$548.00</td>
</tr>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$576.00</td>
<td>$561.00</td>
</tr>
<tr>
<td>Brian Brophy</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$609.00</td>
<td>$559.00</td>
</tr>
<tr>
<td>Patrick Tyler Brown</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$597.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Steven Fisher</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$491.00</td>
<td>-</td>
</tr>
<tr>
<td>Garik Shmois</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$615.00</td>
<td>$645.00</td>
</tr>
<tr>
<td>Adrian Heurta</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$560.00</td>
<td>$640.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Martin Marietta Materials. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Martin Marietta Materials compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Martin Marietta Materials's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Martin Marietta Materials's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MLM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Martin Marietta Materials analyst ratings.</a>
<h2>Discovering Martin Marietta Materials: A Closer Look</h2>
Martin Marietta Materials is one of the United States' largest producer of construction aggregates (crushed stone, sand, and gravel). In 2024, Martin Marietta sold 191 million tons of aggregates. Martin Marietta's most important markets include Texas, Colorado, North Carolina, Georgia, and Florida, accounting for most of its sales. The company also produces cement in Texas and uses its aggregates in its asphalt and ready-mixed concrete businesses. Martin's magnesia specialties business produces magnesia-based chemical products and dolomitic lime.
<h3>Martin Marietta Materials: A Financial Overview</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Martin Marietta Materials's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 8.15%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Materials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 8.57%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Martin Marietta Materials's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.25%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Martin Marietta Materials's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.65%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a high debt-to-equity ratio of 0.64, Martin Marietta Materials faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Martin Marietta Materials Stock: Analyst Perspectives (8 Ratings)

Cleanspark's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NYSE">CLSK</a>) short percent of float has fallen 3.83% since its last report. The company recently reported that it has 72.21 million shares sold short, which is 26.4% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.41 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Cleanspark Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750078822_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cleanspark has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Cleanspark's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Cleanspark's peer group average for short interest as a percentage of float is 14.46%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CLSK

Looking Into Cleanspark's Recent Short Interest

Throughout the last three months, 14 analysts have evaluated Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $60.57, with a high estimate of $76.00 and a low estimate of $40.00. Observing a 0.23% increase, the current average has risen from the previous average price target of $60.43. 
<img src="https://www.benzinga.com/files/images/story/2025/1750078815_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Celanese by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$66.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$55.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$61.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$62.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Jeffrey Hammond</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$76.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Bradley Thomas</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$71.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$48.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Stephen Richardson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$75.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$76.00</td>
<td>$76.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Celanese. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Celanese compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Celanese's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Celanese's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Celanese analyst ratings.</a>
<h2>About Celanese</h2>
Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.
<h3>A Deep Dive into Celanese's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Celanese's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -8.5%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Celanese's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.88% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Celanese's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.41%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Celanese's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.09%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.53, caution is advised due to increased financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 14 Analysts Discuss Celanese Stock

JFBRW

Trading Halt: Halt status updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times

This Collaboration Integrates SaverOne's VRU Detection Solution into an ADAS Platform for Enhanced Road Safety
Petah Tikvah, Israel, June 16, 2025 (GLOBE NEWSWIRE) -- SaverOne 2014 Ltd. (NASDAQ:<a href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>, TASE: SVRE)), a technology company engaged in innovative transportation safety solutions, today announced the signing of a preliminary agreement with a leading European-based automotive-technology provider, dedicated to providing&nbsp;sensor solutions. The collaboration will integrate SaverOne's Vulnerable Road User (VRU) detection solution with its Advanced Driver Assistance Systems (ADAS) sensor fusion platform, introducing a non-line-of-sight VRU detection capability to their ADAS sensor fusion platform. &nbsp;
This marks a key milestone for SaverOne's VRU solution, with its first agreement involving sensor fusion collaboration. The joint initiative will integrate SaverOne's Radio Frequency (RF) detection technology into the technology provider's sensor fusion platform, generating a fused and detailed environmental model. The combined system is expected to vastly improve the detection of Vulnerable Road Users (VRUs) such as pedestrians, specifically in Non-Line-of-Sight (NLoS) scenarios. This enhanced situational awareness is intended to enable more accurate and safer decisions by the vehicle's ADAS systems. The integrated system is expected to be showcased to OEM customers at the ADAS provider's main European showroom.

Saverone Signs Preliminary Agreement With European ADAS Technology Provider To Integrate Saverone's VRU Detection Solution With ADAS Sensor Fusion Platform

JP Morgan analyst Tien-Tsin Huang maintains Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) with a Overweight and raises the price target from $349 to $353.

Price Target

JP Morgan Maintains Overweight on Accenture, Raises Price Target to $353

JP Morgan analyst Brian Essex maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Overweight and raises the price target from $292 to $348.

JP Morgan Maintains Overweight on Zscaler, Raises Price Target to $348

CTLP

Trading Halt: Halted at 8:55:23 a.m. ET - Trading Halt: Halt News Pending

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

GCTK

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) announced on Monday that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—would soon be available in single-dose vials for $499 per month through LillyDirect&#8217;s Self Pay Pharmacy Solutions and the Zepbound <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">Self Pay Journey Program</a>.
Healthcare providers can begin prescribing the 12.5 mg and 15 mg vials on July 7; shipments to patients will begin in early August.
With the addition of these doses, every strength of Zepbound vial will be available for&nbsp;$499/month or less ($349&nbsp;for the 2.5 mg starter dose) to any eligible adult with obesity and a valid prescription, regardless of insurance.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45834370/eli-lillys-obesity-drug-success-spurs-japanese-biotechs-anti-muscle-wasting-combo-therapy" rel="noreferrer noopener">Eli Lilly&#8217;s Obesity Drug Success Spurs Japanese Biotech&#8217;s Anti-Muscle-Wasting Combo Therapy</a>
Zepbound is an injectable prescription medicine that may help adults with obesity or some overweight adults with weight-related medical problems to lose excess body weight and <a href="https://www.benzinga.com/pressreleases/25/06/n45945218/lilly-to-offer-all-approved-doses-of-zepbound-tirzepatide-single-dose-vials-through-lillydirect-se" target="_blank" rel="noreferrer noopener">keep the weight off</a>.
It may also help adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.
Patients with obesity who choose to self-pay will soon be able to access Zepbound single-dose vials, including 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.
Patients on the 2.5 mg starter dose will pay&nbsp;$349&nbsp;for their first month, then&nbsp;$499&nbsp;per month for the 5 mg dose, which is the next step in treatment.
Through the Zepbound Self Pay Journey Program, designed to support patients throughout their obesity treatment journey, the 7.5 mg&nbsp;($599), 10 mg&nbsp;($699), 12.5 mg&nbsp;($849), and 15 mg&nbsp;($1,049)&nbsp;doses will be available at a reduced monthly cost of&nbsp;$499&nbsp;for the first fill and refills made within 45 days of the prior delivery.
The recommended starting dosage is 2.5 mg, which is taken once weekly for four weeks.
After four weeks, the dosage is increased to 5 mg. The health care provider may increase the dosage in 2.5 mg increments after at least four weeks on the current dose until the recommended maintenance dosage is achieved. 
The 2.5 mg starting dose is not an approved maintenance dose. The maximum dose is 15 mg.
Zepbound is also available in a single-dose pen (autoinjector) in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL dose.
The 2.5 mg is a starting dose and not an approved maintenance dose. The recommended maintenance doses are 5 mg, 10 mg, or 15 mg, injected subcutaneously once per week for weight reduction and long-term maintenance, and 10 mg or 15 mg for OSA.
In a 72-week study of adults without diabetes, average weight loss was 15.0% (34 lbs) for 5 mg, 19.5% (44 lbs) for 10 mg, 20.9% (48 lbs) for 15 mg, and 3.1% (7 lbs) for placebo.
Average starting weights were 226.8 lbs for 5 mg, 233.3 lbs for 10 mg, 232.8 lbs for 15 mg, and 231.0 lbs for placebo.
In another 72-week study of adults with diabetes, average weight loss was 12.8% (28 lbs) for 10 mg, 14.7% (33 lbs) for 15 mg, and 3.2% (7 lbs) for placebo.
Further assessment of data for the 72-week study of adults without diabetes showed that the percent who saw ≥25% body weight loss (57-58 lbs) was 15.3% for 5 mg, 32.3% for 10 mg, 36.2% for 15 mg, and 1.5% for placebo.
Price Action: At the last check on Monday, LLY stock was up 0.75% at $825.50 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45927887/novo-nordisk-moves-amycretin-into-phase-3-trials-for-weight-management-becomes-europes-largest-company" target="_blank" rel="noreferrer noopener">Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe&#8217;s Largest Company</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

General

Eli Lilly Launches Flat Pricing For Zepbound, Capping Monthly Cost At $499

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the energy sector.
<h3 class="wp-block-heading">Delek Logistics Partners, LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKL#NYSE">DKL</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 10.21%</li>
<li>Raymond James analyst Justin Jenkins maintained an Outperform rating and raised the price target from $44 to $46 on Jan. 28, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Truist Securities analyst Neal Dingmann maintained a Buy rating and increased the price target from $46 to $50 on Nov. 18, 2024. This analyst has an accuracy rate of 60%.</li>
<li>Recent News: On May 7, Delek Logistics Partners posted downbeat quarterly earnings</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0616">latest DKL news.</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0616"><img loading="lazy" decoding="async" width="920" height="850" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16084829/image-238.png" alt="" class="wp-image-950723" style="width:626px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16084829/image-238.png 920w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16084829/image-238-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16084829/image-238-768x710.png 768w" sizes="(max-width: 920px) 100vw, 920px" /></a></figure>
<h3 class="wp-block-heading">Mach Natural Resources LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNR#NYSE">MNR</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 21.51%</li>
<li>Raymond James analyst John Freeman reiterated a Strong Buy rating and increased the price target from $23 to $25 on Feb. 10, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Stifel analyst Selman Akyol maintained a Buy rating and increased the price target from $21 to $23 on Feb. 7, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Recent News: On May 8, Mach Natural Resources posted downbeat quarterly earnings.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0616">latest MNR news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0616"><img loading="lazy" decoding="async" width="917" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16084902/image-239.png" alt="" class="wp-image-950724" style="width:564px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16084902/image-239.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16084902/image-239-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16084902/image-239-768x709.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">Vitesse Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTS#NYSE">VTS</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 9.22%</li>
<li>Roth MKM analyst John White maintained a Buy rating and raised the price target from $30.5 to $33 on April 2, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Evercore ISI Group analyst Chris Baker reinstated an In-Line rating with a price target of $28 on March 19, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On May 5, Vitesse Energy reported upbeat earnings for the first quarter, but lowered its FY 2025 production guidance.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest VTS <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0616">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0616"><img loading="lazy" decoding="async" width="903" height="826" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16084934/image-240.png" alt="" class="wp-image-950725" style="width:600px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16084934/image-240.png 903w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16084934/image-240-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16084934/image-240-768x703.png 768w" sizes="(max-width: 903px) 100vw, 903px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45946608/top-3-materials-stocks-that-could-blast-off-this-month-3">Top 3 Materials Stocks That Could Blast Off This Month</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Dividends

Wall Street's Most Accurate Analysts Spotlight On 3 Energy Stocks Delivering High-Dividend Yields

Polestar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) announces a USD 200 million equity investment by PSD Investment Limited ("PSD Investment"), an existing investor, an entity that is controlled by Mr. Shufu (Eric) Li, Founder and Chairman of Geely Holding Group.
Polestar Automotive Holding UK PLC ("Polestar") has entered into a securities purchase agreement pursuant to which Polestar agreed to sell newly issued 190,476,190 Class A American Depositary Shares ("ADS") to PSD Investment for an aggregate price of USD 200,000,000 through a private investment in public equity ("PIPE") at a price of $1.05 per Class A ADS, which represents the volume weighted average closing sale price for the previous five consecutive trading days prior to signing. Prior to closing of the PIPE, PSD Investment intends to convert 20,000,000 of its Class B ADS shares into Class A ADS shares in order to keep the overall voting power of its Polestar shareholdings below 50%. Polestar intends to use the proceeds from the equity investment for working capital requirements and general corporate purposes.

Offerings

Contracts

PSNY

Polestar Announces $200M PIPE Equity Investment By PSD Investment At $1.05 Per ADS With 190,476,190 New Class A ADS Issued; PSD To Convert 20M Class B ADS To Maintain Voting Power Below 50%

Aerospace and defense giant RTX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) has announced a series of major deals for its Pratt &amp; Whitney division. The new agreements span commercial aviation and defense, including contracts with Frontier Airlines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>), Cebu Pacific, and Dynetics.
Frontier Airlines <a href="https://www.benzinga.com/pressreleases/25/06/n45944440/frontier-airlines-selects-rtxs-pratt-whitney-gtf-engines-to-power-91-airbus-a321neo-aircraft">announced on Monday</a> that it has selected Pratt &amp; Whitney&#8217;s GTF engines, part of RTX Corp., to power 91 new Airbus A321neo aircraft. 
The announcement, made by Pratt &amp; Whitney, a division of RTX, and Frontier Airlines, also includes a long-term EngineWise Comprehensive service agreement for the maintenance of these engines.
Also Read: <a href="https://www.benzinga.com/markets/large-cap/25/06/45944828/southwest-airlines-to-equip-entire-boeing-737-fleet-with-honeywells-runway-safety-technology" target="_blank" rel="noreferrer noopener">Southwest Airlines To Equip Entire Boeing 737 Fleet With Honeywell&#8217;s Runway Safety Technology</a>
Rick Deurloo, president of Commercial Engines at Pratt &amp; Whitney, expressed his satisfaction with the continued partnership, stating, &#8220;This selection demonstrates the airline&#8217;s confidence in the GTF engine.&#8221; He highlighted the engine&#8217;s fuel efficiency as a key benefit for the single-aisle aircraft market.
The new A321neo aircraft for Frontier will be equipped with the GTF Advantage engine, an advanced version of the GTF engine. The GTF Advantage is designed to offer increased take-off thrust, enhanced fuel efficiency, and longer operational time between maintenance events. This engine is expected to become the standard production model in the coming years.
Separately, Cebu Pacific signed a 12-year <a href="https://www.benzinga.com/pressreleases/25/06/n45945216/rtxs-pratt-whitney-and-cebu-pacific-sign-long-term-engine-maintenance-deal" target="_blank" rel="noreferrer noopener">EngineWise maintenance deal</a> with Pratt &amp; Whitney for its GTF engine fleet. The agreement ties maintenance costs to engine use, offering predictable budgeting and operational efficiency as the airline grows.
It covers GTF engines for up to 152 A321neo and 15 A320neo aircraft ordered in 2024. Cebu Pacific CEO Mike Szucs said the engines reduce fuel burn by up to 20%, supporting sustainability and cost savings.
In defense, Pratt &amp; Whitney announced that it has secured a contract with Dynetics, a Leidos Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) company. Under the agreement, Pratt &amp; Whitney will provide its <a href="https://www.benzinga.com/pressreleases/25/06/n45945433/rtxs-pratt-whitney-to-provide-affordable-mass-propulsion-for-leidos-small-cruise-missile-program">TJ150 turbojet engines</a> to power Dynetics&#8217; Small Cruise Missile, known as the Black Arrow.
Work on the current contract began in April 2025 and is expected to continue through the first quarter of 2026, with an option for follow-on engine orders. 
Related ETFs: U.S. Global Jets ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JETS#NYSE">JETS</a>), iShares U.S. Aerospace &amp; Defense ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ITA#BATS">ITA</a>).
Price Action: RTX shares are trading higher by 0.90% to $147, and ULCC was up 2.33% at $3.51 premarket at last check Monday.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45944854/irans-missile-stockpile-may-be-shrinking-as-strikes-on-israel-taper-off-says-think-tank-lmt-rtx-gd-in-focus" target="_blank" rel="noreferrer noopener">Iran&#8217;s Missile Stockpile May Be Shrinking As Strikes On Israel Taper Off, Says Think Tank: LMT, RTX, GD In Focus</a></li>
</ul>
Photo by T. Schneider via Shutterstock

JETS

LDOS

ULCC

RTX Scores Major Aviation And Defense Deals With Frontier, Cebu Pacific, And Dynetics

JP Morgan analyst Seth Seifman maintains Leonardo DRS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRS#NASDAQ">DRS</a>) with a Neutral and raises the price target from $33 to $48.

JP Morgan Maintains Neutral on Leonardo DRS, Raises Price Target to $48

WIIM

PRTA

Prothena shares are trading higher after the company annoucned its partner, Roche, will advance prasinezumab, an investigational anti-alpha-synuclein antibody, into Phase III development in early-stage Parkinson's disease.

<a href="https://www.globenewswire.com/Tracker?data=K8NHs4yRE6i9-O9qYQfqd88Xhy4Ze_bY9R5fMAn3Uo0v0cANvPE0B3ftZfqh1jVUC74cZebYsW4Dy1qtm8XZroakMjD0vqG0j8BNI4wyijemunMVklBfC4D6pjk-Bzpj">SS Innovations International, Inc.</a> (the "Company" or "SS Innovations") (NASDAQ:<a href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the first robotic cardiac surgery in the Americas and Western Hemisphere has been successfully performed utilizing the Company's SSi Mantra 3 surgical robotic system. On June 8, 2025, Dr. Juan Zuniga, a cardiothoracic surgeon from Interhospital in Guayaquil, Ecuador, became the first surgeon to perform a robotic cardiac surgery in the Americas and Western Hemisphere using the SSi Mantra 3. The surgery involved a robotic Atrial Septal Defect closure, a procedure that repairs a hole between the upper two chambers of the heart.

SSII

SS Innovations Performs First Robotic Cardiac Surgery In Americas And Western Hemisphere Utilizing SSi Mantra 3 Surgical Robotic System

Press Releases

Cartesian Therapeutics Announces New Employment Inducement Grant

Earnings

Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

Comments

Cartesian Therapeutics

Noticias

Últimas noticias sobre Cartesian Therapeutics (NASDAQ:RNAC) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL